Quick Answer
Fortress Biotech, Inc. reported Diluted EPS of $0.07 per share (loss) for fiscal year 2025.
Fortress Biotech, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.07 | +97.4% |
| 2024 | -$2.69 | +68.2% |
| 2023 | -$8.47 | +47.0% |
| 2022 | -$15.97 | -1921.5% |
| 2021 | -$0.79 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.11 | +114.5% | -75.6% |
| June 30, 2025 | $0.45 | +161.6% | +193.8% |
| March 31, 2025 | -$0.48 | +53.8% | +36.8% |
| September 30, 2024 | -$0.76 | +19.1% | -4.1% |
| June 30, 2024 | -$0.73 | +80.0% | +29.8% |
| March 31, 2024 | -$1.04 | -395.2% | -10.6% |
| September 30, 2023 | -$0.94 | +77.1% | +74.2% |
| June 30, 2023 | -$3.65 | -1303.8% | -1638.1% |
- Fortress Biotech, Inc. showed an increase of +97.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Fortress Biotech, Inc.’s diluted eps has grown by 91.1% (from $0.79 per share (loss) to $0.07 per share (loss)).
- The most recent figure is from Fortress Biotech, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: